Established by amalgamation in 1995, Helix is publicly listed, with its common shares traded on the Toronto Stock Exchange. In addition, the Corporation is quoted on the Frankfurt, Munich, Stuttgart and Berlin stock exchanges. Helix's trading symbol is "HBP." Helix is actively researching a host of potential new anti-cancer drug-products based on its proprietary core technologies. The company is committed to investigating new directions in the field of cancer therapy by exploiting new technologies for and approaches to drug development and disease management. Helix's business strategy is to commercialize the drug products they develop on a royalty-bearing basis via third-party licensing arrangements, a strategy demonstrated with its first successfully launched product, Klean-Prep(TM). Helix, however, considers all appropriate commercialization and exploitation strategies for its emerging drug-products, and pursues opportunities to commercialize our core technologies separately.